EUVIMEDEUVIMED entdecken
Systematische ÜbersichtVergleichsstudie

A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review

Sabrina Wong, Angela T H Kwan, Kayla M Teopiz, Gia Han Le, Shakila Meshkat, Roger Ho, Giacomo d'Andrea, Bing Cao, Joshua D Di Vincenzo, Joshua D Rosenblat, Roger S McIntyre

Journal of Affective Disorders · 2024

DOI: 10.1016/j.jad.2024.01.142 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Affective Disorders, 2024. Verfasst von Sabrina Wong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontari…. Hauptthemen laut MEDLINE: Psilocybin, Ketamine, Depressive Disorder, Treatment-Resistant, Antidepressive Agents. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Milken Institute, Canadian Institutes of Health Research, AbbVie Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Inadequate outcomes with monoamine-based treatments in depressive disorders are common and provide the impetus for mechanistically-novel treatments. Esketamine is a proven treatment recently approved for adults with Treatment-Resistant Depression (TRD) while psilocybin is an investigational treatment. Translation of the clinical meaningfulness for these foregoing agents in adults with TRD is required. Herein we evaluate the Number Needed to Treat (NNT) and Harm (NNH) of esketamine and psilocybin in adults with TRD. METHODS: We conducted a systematic review of randomized controlled trials, comparing the clinical efficacy of oral psilocybin to the co-commencement of intranasal esketamine with an oral antidepressant in adults with TRD. RESULTS: 25 mg psilocybin had a significant reduction in depressive symptoms at 21-days post-dose, the NNT was 5 [95 % CI = 3.1, 18.5]. Psilocybin-induced nausea had a significant NNH = 5. Fixed-dosed esketamine at 56 mg and 84 mg had a significant effect at 28-days post-dose, (NNT of 7 [95 % CI56mg = 3.5, 46.7], [95 % CI84mg = 3.6, 142.2]). Esketamine-induced headache, nausea, dizziness, and dissociation had NNHs

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsilocybinKetamineDepressive Disorder, Treatment-ResistantAntidepressive AgentsHumansRandomized Controlled Trials as TopicAdministration, IntranasalHallucinogensTreatment OutcomeAdult

Stichwörter der Autor:innen

EsketamineNumber needed to treatPsilocybinTreatment-resistant depression

Substanzen

PsilocybinKetamineEsketamineAntidepressive AgentsHallucinogens

Autor:innen und Institutionen

  • Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
  • Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada; Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario…
  • Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada.
  • Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Toron…
  • Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada.
  • Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapo…

Förderung

  • Milken Institute
  • Canadian Institutes of Health Research
  • AbbVie Canada
  • National University of Singapore
  • National Natural Science Foundation of China
  • Global Alliance for Chronic Diseases

Zitieren

APA

Wong, S., Kwan, A. T. H., Teopiz, K. M., Le, G. H., Meshkat, S., Ho, R., d'Andrea, G., Cao, B., Di Vincenzo, J. D., Rosenblat, J. D., & McIntyre, R. S. (2024). A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2024.01.142

Vancouver

Wong S, Kwan ATH, Teopiz KM, Le GH, Meshkat S, Ho R, et al. A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review. Journal of Affective Disorders. 2024. doi:10.1016/j.jad.2024.01.142

BibTeX
@article{Wong2024,
  author = {Wong, Sabrina and Kwan, Angela T H and Teopiz, Kayla M and Le, Gia Han and Meshkat, Shakila and Ho, Roger and d'Andrea, Giacomo and Cao, Bing and Di Vincenzo, Joshua D and Rosenblat, Joshua D and McIntyre, Roger S},
  title = {A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review},
  journal = {Journal of Affective Disorders},
  year = {2024},
  doi = {10.1016/j.jad.2024.01.142}
}
Kostenlos starten →